Amarin's Vascepa reigns supreme in fish oil battle, as AstraZeneca's rival fizzles
AstraZeneca’s competitive threat to Amarin’s mighty Vascepa in patients with cardiovascular risk has wilted.
On Monday, the British drugmaker said it was abandoning a large cardiovascular (CV) outcomes trial testing its fish oil pill Epanova after an independent data monitoring committee predicted the therapy had a low likelihood of demonstrating a benefit to patients with mixed dyslipidaemia who carry a high risk of CV disease.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.